Contribute Try STAT+ Today

A bipartisan group of lawmakers has accused the U.S. Patent & Trademark Office of “weakening” the system for challenging patents and, as a result, encouraging abuses by drug makers that seek to thwart the availability of lower-cost generic medicines.

At issue is the inter partes review, or IPR, which went into effect in 2012 as a result of the America Invents Act. This type of patent challenge, which is heard by the Patent and Trials Appeal Board, was intended to provide an easier and faster alternative to patent infringement lawsuits filed in federal courts. For this reason, the IPR process has irked brand-name pharmaceutical companies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment